First Tracks Biotherapeutics Inc
NASDAQ: TRAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel R. Faga
- Employees
- 104
- Headquarters
- San Diego, United States
- IPO year
- 2026
- Market cap
- $648.6M
- Website
- https://www.firsttracksbio.com
Loading TRAX…
Loading profile data…Frequently asked questions about TRAX
What does First Tracks Biotherapeutics Inc (TRAX) do?
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their c...
Where does TRAX trade?
First Tracks Biotherapeutics Inc (TRAX) trades on the NASDAQ Global Select.
What sector is TRAX in?
First Tracks Biotherapeutics Inc (TRAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of First Tracks Biotherapeutics Inc?
Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics Inc (TRAX).
Where is First Tracks Biotherapeutics Inc headquartered?
First Tracks Biotherapeutics Inc is headquartered in United States.
Does TRAX pay a dividend?
First Tracks Biotherapeutics Inc (TRAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TRAX go public?
First Tracks Biotherapeutics Inc (TRAX) completed its initial public offering in 2026.